Authors: Buchner, T Hiddemann, W Berdel, W Wormann, B Loffler, H Schoch, C Haferlach, T Ludwig, WD Maschmeyer, G Staib, P Andreesen, R Balleisen, L Haase, D Eimermacher, H Aul, C Rasche, H Uhlig, J Gruneisen, A Reis, HE Hartlapp, J Hirschmann, WD Weh, HJ Pielken, HJ Gassmann, W Sauerland, MC Heinecke, A

Citation: T. Buchner et al., Remission induction therapy: the more intensive the better?, CANC CHEMOT, 48, 2001, pp. S41-S44

Authors: Buchner, T Hiddemann, W Schoch, C Haferlach, T Eimermacher, H Staib, P Balleisen, L Reis, HE Pielken, HJ Reichle, A Schmoll, HJ Griesinger, F Gruneisen, A Sauerland, MC Heinecke, A

Citation: T. Buchner et al., Treatment of older patients with acute myeloid leukemia (AML), HEMAT BLOOD, 40, 2001, pp. 611-620

Authors: Buchner, T Hiddemann, W Wormann, B Loffler, H Ludwig, WD Schoch, C Haferlach, T Maschmeyer, G Staib, P Aul, C Heyll, A Gruneisen, A Rasche, H Eimermacher, H Balleisen, L Pielken, HJ Reis, HE Griesinger, F Reichle, A Sauerland, MC Heinecke, A

Citation: T. Buchner et al., Acute myeloid leukemia in adults: Is postconsolidation maintenance therapynecessary?, INT J HEMAT, 72(3), 2000, pp. 285-289

Authors: Verbeek, W Wormann, B Koch, P Aul, C Hinrichs, HF Balleisen, L Rowe, JM Bennett, J Haase, D Fonatsch, C Heinecke, A Buchner, T Hiddemann, W

Citation: W. Verbeek et al., Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes, J CANC RES, 125(6), 1999, pp. 369-374